Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy

Clinical Cancer Research

Volumn 14, Issue 7, 2008, Pages 2082-2087

  Dubsky, Peter ^a   Sevelda, Paul ^b   Jakesz, Raimund ^a   Hausmaninger, Hubert ^d   Samonigg, Hellmut ^e   Seifert, Michael ^a   Denison, Ursula ^b   Mlineritsch, Brigitte ^d   Steger, Günther ^a   Kwasny, Werner ^f   Stöger, Herbert ^e   Bartsch, Rupert ^a   Stierer, Michael ^c   Taucher, Susanne ^a   Fridrik, Michael ^g   Schippinger, Walter ^e   Greil, Richard ^d   Pötter, Richard ^a   Gnant, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

^c HANUSCH HOSPITAL   (Austria)

^d Private Medical University Hospital   (Austria)

^e UNIVERSITY OF GRAZ   (Austria)

^f Hospital Wiener Neustadt   (Austria)

^g KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ADULT; ANEMIA; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; METHOTREXATE; PREMENOPAUSE; PROGNOSIS; RADIOTHERAPY;

EID: 42249088730     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2068     Document Type: Article

References (27)

1. Denison U, Baumann J, Peters-Engl C, et al. Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 2003;79:347-53.
2. Birgegard G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005;68:3-11.
3. Groopman JE, Itri LM Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34.
4. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-21.
5. Boehm DU, Lebrecht A, Schmidt M, et al. Prognostic impact of haemoglobin levels in breast cancer. Anticancer Res 2007;27:1223-6.
6. Hu K, Harrison LB. Impact of anemia in patients with head and neck cancer treated with radiation therapy. Curr Treat Options Oncol 2005;6:31-45.
7. Choi YS, Yi CM, Sin JI, Ye GW, Shin IH, Lee TS. Impact of hemoglobin on survival of cervical carcinoma patients treated with concurrent chemoradiotherapy is dependent on lymph node metastasis findings by magnetic resonance imaging. Int J Gynecol Cancer 2006;16:1846-54.
8. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-36.
9. Dunphy EP, Petersen IA, Cox RS, Bagshaw MA. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1989;16:1173-8.
10. Henke M, Sindlinger F, Ikenberg H, Gerds T, Schumacher M. Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol 2004;180:45-51.
11. Bottini A, Berruti A, Brizzi MP, et al. Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer. Br J Cancer 2003;89:977-82.
12. Beresford MJ, Burcombe R, Ah-See ML, Stott D, Makris A. Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer. Clin Oncol (R Coll Radiol) 2006;18:453-8.
13. Vaupel P, Mayer A, Briest S, Hockel M. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 2003;63:7634-7.
14. Vaupel P, Mayer A, Hockel M. Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 2006;182:63-71.
15. Helczynska K, Kronblad A, Jogi A, et al. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 2003;63:1441-4.
16. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
17. Vaupel P, Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol 2005;12:5-10.
18. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007;356:2445-8.
19. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14.
20. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
21. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer J Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20:4621-7.
22. Overgaard J, Hansen HS, Jorgensen K, Hjelm Hansen M. Primary radiotherapy of larynx and pharynx carcinoma-an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys 1986;12:515-21.
23. Kamby C, Sengelov L. Survival and pattern of failure following locoregional recurrence of breast cancer. Clin Oncol (R Coll Radiol) 1999;11:156-63.
24. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465-72.
25. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001;18:243-59.
26. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
27. Patiar S, Harris AL. Role of hypoxia-inducible factor-1α as a cancer therapy target. Endocr Relat Cancer 2006;13:S61-75.